| Literature DB >> 34109284 |
Mengjia Wu1, Yi Zhang1, Mark Grosser2, Steven Tipper2, Deon Venter2, Hua Lin2, Jie Lu1.
Abstract
The COVID-19 pandemic constitutes an ongoing worldwide threat to human society and has caused massive impacts on global public health, the economy and the political landscape. The key to gaining control of the disease lies in understanding the genetics of SARS-CoV-2 and the disease spectrum that follows infection. This study leverages traditional and intelligent bibliometric methods to conduct a multi-dimensional analysis on 5,632 COVID-19 genetic research papers, revealing that 1) the key players include research institutions from the United States, China, Britain and Canada; 2) research topics predominantly focus on virus infection mechanisms, virus testing, gene expression related to the immune reactions and patient clinical manifestation; 3) studies originated from the comparison of SARS-CoV-2 to previous human coronaviruses, following which research directions diverge into the analysis of virus molecular structure and genetics, the human immune response, vaccine development and gene expression related to immune responses; and 4) genes that are frequently highlighted include ACE2, IL6, TMPRSS2, and TNF. Emerging genes to the COVID-19 consist of FURIN, CXCL10, OAS1, OAS2, OAS3, and ISG15. This study demonstrates that our suite of novel bibliometric tools could help biomedical researchers follow this rapidly growing field and provide substantial evidence for policymakers' decision-making on science policy and public health administration.Entities:
Keywords: COVID-19; bibliometrics; genetic research; knowledge discovery; network analytics
Year: 2021 PMID: 34109284 PMCID: PMC8184093 DOI: 10.3389/frma.2021.683212
Source DB: PubMed Journal: Front Res Metr Anal ISSN: 2504-0537
FIGURE 1The research framework.
FIGURE 2Monthly trend of the number of publications.
Top 20 prolific countries, research institutions and journals in this emerging field.
| Ranking | Country | Research Institution | Journal |
|---|---|---|---|
| 1 | United States (1811) | University of California (183)—United States | Journal of Medical Virology (150) |
| 2 | China (1,030) | University of Texas (104)—United States | PLoS One (130) |
| 3 | United Kingdom (560) | University of Hong Kong (93)—China | Scientific Reports (100) |
| 4 | Italy (534) | University of Oxford (92)—United Kingdom | Nature (88) |
| 5 | Germany (359) | Wuhan University (76)—China | Viruses (82) |
| 6 | India (320) | University of Washington (76)—United States | Nature Communication (70) |
| 7 | France (299) | University of Pennsylvania (71)—United States | Frontiers in Immunology (70) |
| 8 | Canada (274) | Stanford University (63)—United States | International Journal of Infectious Diseases (68) |
| 9 | Spain (214) | University College London (59)—United Kingdom | Science (67) |
| 10 | Australia (196) | University of Cambridge (58)—United Kingdom | Emerging Microbes & Infections (64) |
| 11 | Brazil (173) | Massachusetts General Hospital (58)—United States | Journal of Clinical Virology (62) |
| 12 | Japan (150) | University of Chinese Academy of Sciences (55)—China | Medical Hypotheses (62) |
| 13 | Switzerland (141) | Tongji Hospital (54)—China | International Journal of Molecular Sciences (57) |
| 14 | Iran (140) | Columbia University (52)—United States | Cell (50) |
| 15 | South Korea (115) | University of Toronto (52)—Canada | Journal of Clinical Microbiology (46) |
| 16 | Belgium (105) | University of Edinburgh (51)—United Kingdom | Infection, Genetics and evolution (45) |
| 17 | Turkey (98) | University of Milan (51)—Italy | Signal Transduction and Targeted Therapy (44) |
| 18 | Sweden (88) | Brigham and Women’s Hospital (51)—United States | Proceedings of the National Academy of Sciences of the United States of America (42) |
| 19 | Saudi Arabia (67) | Peking Union Medical College (50)—China | BMC Infectious Diseases (41) |
| 20 | Austria (67) | Fudan University (48)—China | Eurosurveillance (39) |
FIGURE 3The co-authorship network of research institutions (normalized by Jaccard Coefficient).
FIGURE 4The co-occurrence network of scientific terms.
FIGURE 5The SEP on COVID-19 genetic research between January 2020 and April 2021.
The basic statistics of 85 topics.
| Node number | Maximum publication number | Minimum publication number | Standard deviation |
|---|---|---|---|
| 85 | 321 | 3 | 84.374 |
| MERS-CoV [2020 January]—321 | Etiological agent [2021 January]—3 | ||
| SARS-CoV [2020 January]—320 | Human lung [2021 January]—3 | ||
| Transcription [2020 May]—309 | Cell count [2021 February]—3 | ||
| Pneumonia [2020 June]—208 | Healthcare worker [2021 February]—3 |
We list the top four topics that contain the largest/smallest numbers of publications in the table.
Stepwise results of the pre-processing procedure.
| Raw | Step 1 | Cleaned | Step 2 | Nodes | |
|---|---|---|---|---|---|
| Disease | 31,974 | Removed noisy concepts like “cardioembolic”, “JAGS”, “nonvitamin”, etc. that could not be mapped to MeSH | 31,963 | MeSH | 801 |
| Chemical | 4,494 | 3,724 | 678 | ||
| Gene | 11,211 | Excluded genes that do not belong to | 8,781 | NCBI Gene | 968 |
| Gene variant | |||||
| DNA mutation | 69 | Removed variants with unclear loci (i.e., could not be mapped to an SNP ID) | 17 | dbSNP | 126 |
| Protein mutation | 349 | 91 | |||
| SNP | 104 | — | 104 | ||
| Total | 48,201 | — | 44,680 | — | 2,573 |
Counts of the different types of edges.
| Disease | Chemical | Gene | Genetic variant | |
|---|---|---|---|---|
| Disease | 8,231 | 4,872 | 6,966 | 499 |
| Chemical | 4,872 | 2,121 | 2,268 | 37 |
| Gene | 6,966 | 2,268 | 5,692 | 385 |
| Genetic Variant | 499 | 37 | 385 | 777 |
The top 10 entities ranked by the raw frequency.
| Ranking | Disease | Chemical | Gene | Genetic variant |
|---|---|---|---|---|
| 1 | Death | Oxygen |
| rs2285666 |
| 2 | Pneumonia | Hydroxychloroquine |
| rs12329760 |
| 3 | Inflammation | Remdesivir |
| rs4646116 |
| 4 | Fever | Serine |
| rs11385942 |
| 5 | Neoplasms | Chloroquine |
| rs12252 |
| 6 | Respiratory distress syndrome, adult | Lipids |
| rs1244687367 |
| 7 | Cough | Azithromycin |
| rs143936283 |
| 8 | Diabetes mellitus | Lopinavir-ritonavir drug combination |
| rs73635825 |
| 9 | Hypertension | Nitrogen |
| rs8176746 |
| 10 | Zoonoses | Aldosterone |
| rs8176719 |
FIGURE 6Top 10 genes (A), co-morbidities (B) and chemicals (C) in COVID-19 genetic research between December 2019 and January 2021.
FIGURE 7Emerging gene discovery for COVID-19 genetic research.
FIGURE 8Emerging gene discovery for COVID-19 genetic research–detailed partial view. Note: This figure is a zoom-in map for the red broken-line box in Figure 7.